Stroke Clinical Trial
— BEACHOfficial title:
Boston Scientific EPI: A Carotid Stenting Trial for High-Risk Surgical Patients
Verified date | August 2014 |
Source | Boston Scientific Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be less than or equal to that of objective performance criteria (OPC) derived from historic controls undergoing surgical intervention with a carotid endarterectomy (CEA).
Status | Completed |
Enrollment | 747 |
Est. completion date | November 2007 |
Est. primary completion date | May 2005 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Key General Inclusion Criteria: - Patient must meet criteria for either A or B: A. Symptomatic: Carotid stenosis of greater than or equal to 50% via angiography with associated cerebral or retinal TIA or ischemic stroke symptoms within 180 days of the procedure, which are determined to have occurred in the cerebral hemisphere or eye ipsilateral to the target carotid artery lesion and to be reasonably attributable to that lesion; or B. Asymptomatic: Carotid stenosis greater than or equal to 80% via angiography without associated cerebral or retinal TIA or ischemic stroke symptoms within 180 days of the procedure. - Target lesion is in the native common carotid artery (CCA), internal carotid artery (ICA), or carotid bifurcation. - Target arterial segment to be stented has a diameter of greater than or equal to 4.0 mm to less than or equal to 9.0 mm. - Vessel diameter distal to the target lesion is greater than or equal to 3.5 mm and less than or equal to 5.5 mm as an optimal "landing zone" for placement of the FilterWire EZ System with visual angiographic recommendations as described in the instructions for use (IFU). Key High-Risk Eligibility Inclusion Criteria: - Patients must qualify in at least one high-risk category. The high-risk categories are defined as: - Anatomical conditions [one (1) criterion qualifies] - Co-morbid conditions Class I [one (1) criterion qualifies] - Co-morbid conditions Class II [two (2) criteria qualify] Exclusion Criteria: - Patient has experienced an evolving, acute, or recent stroke within 21 days of study evaluation. - A total occlusion of the ipsilateral carotid artery. (Only for Roll-In and Pivotal patients.) - A total occlusion of the contralateral carotid artery. (Only for Bilateral Registry patients.) - Pre-existing stent(s): - Roll-In and Pivotal Patients: located within the ipsilateral carotid distribution; a stent was placed in a contralateral vessel within the previous 30 days of the study enrollment. - Bilateral Registry Patients: located within the carotid distribution. - A target lesion which is expected to require more than one stent. - Known cardiac sources of emboli of a type likely to be associated with cerebral ischemic events [e.g. endocarditis, intracardiac thrombus, embolic-associated cardiovascular lesions, or any current arrhythmia (e.g. atrial fibrillation, atrial flutter, etc.)]. - Myocardial infarction (MI) within 72 hours prior to the index procedure, defined as creatine kinase (CK)-MB > 2 X the local laboratory's upper limit of normal (ULN). - Any surgery requiring general anesthesia (e.g. coronary artery bypass graft [CABG], valve replacement, or abdominal aortic aneurysm) less than or equal to 30 days preceding the stent procedure. - The patient is enrolled in another investigational study protocol and has not completed the required follow-up period of the evaluation. The patient may not participate in another investigational study that may confound the treatment or outcomes of the BEACH protocol. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Piedmont Hospital | Atlanta | Georgia |
United States | St. Joseph's Hospital of Atlanta/American Cardiovascular Research Institute | Atlanta | Georgia |
United States | Bapatist Medical Center | Birmingham | Alabama |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Montefiore Medical Center | Bronx | New York |
United States | Kaleida Health/Millard Fillmore Hospital | Buffalo | New York |
United States | Rush Presbyterian-St. Luke's Medical Center | Chicago | Illinois |
United States | Cleveland Clinic & Foundation | Cleveland | Ohio |
United States | Providence Hospital South Carolina Heart Center | Columbia | South Carolina |
United States | Riverside Methodist Hospital | Columbus | Ohio |
United States | Wayne State University- Detroit Medical Center | Detroit | Michigan |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Holy Cross Hospital | Ft. Lauderdale | Florida |
United States | St. Luke's Episcopal Hospital Texas Heart Institute | Houston | Texas |
United States | University of Texas-Houston Medical School | Houston | Texas |
United States | Cape Cod Hospital | Hyannis | Massachusetts |
United States | St. Luke's Hospital of Kansas City | Kansas City | Missouri |
United States | Baptist Hospital of East Tennessee | Knoxville | Tennessee |
United States | Lakeland Regional Medical Center | Lakeland | Florida |
United States | Central Baptist Hospital | Lexington | Kentucky |
United States | Texas Tech University Health Sciences Center | Lubbock | Texas |
United States | Miami Cardiac and Vascular Institute | Miami | Florida |
United States | University of Miami School of Medicine - Jackson Memorial Hospital | Miami | Florida |
United States | Aurora St. Luke's Medical Center | Milwaukee | Wisconsin |
United States | El Camino Hospital | Mountain View | California |
United States | Skyline Medical Center/ Howell Allen Clinic | Nashville | Tennessee |
United States | Ochsner Clinic Foundation | New Orleans | Louisiana |
United States | Lenox Hill Heart and Vascular Institute | New York | New York |
United States | New York Presbyterian Hospital/Columbia Vascular Interventional Radiology | New York | New York |
United States | Hoag Memorial Hospital | Newport Beach | California |
United States | St. Francis Medical Center | Peoria | Illinois |
United States | Hahnemann University/ Tenet Healthcare Corporation | Philadelphia | Pennsylvania |
United States | Arizona Heart Institute | Phoenix | Arizona |
United States | St. Joseph's Hospital & Medical Center | Phoenix | Arizona |
United States | UPMC-Shadyside Hospital Pittsburgh Vascular Institute | Pittsburgh | Pennsylvania |
United States | Northwest Medical Center | Plantation | Florida |
United States | Oregon Health Sciences University | Portland | Oregon |
United States | St. Mary's Hospital | Richmond | Virginia |
United States | Strong Memorial Hospital | Rochester | New York |
United States | St. Francis Hospital | Roslyn | New York |
United States | William Beaumont Hospital | Royal Oak | Michigan |
United States | LDS Hospital | Salt Lake City | Utah |
United States | Baptist Hospital | San Antonio | Texas |
United States | Deaconess Medical Center | Spokane | Washington |
United States | St. John's Hospital - Prairie Heart Institute | Springfield | Illinois |
United States | St. Joseph's Medical Center | Stockton | California |
United States | Medical College of Ohio | Toledo | Ohio |
United States | Washington Hospital Center | Washington | District of Columbia |
United States | Pinnacle Health at Harrisburg Hospital | Wormleysburg | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Boston Scientific Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint is one-year morbidity and mortality, defined as the cumulative incidence of any non Q-wave myocardial infarction within the 24 hours following carotid stenting | 1 year | Yes | |
Primary | peri-procedural (within 30 days of procedure) death, stroke, Q-wave myocardial infarction | Within 30 days of Procedure | Yes | |
Primary | late ipsilateral stroke or death due to neurologic events from 31 days up to and including twelve-month follow-up. | 1 year | Yes | |
Secondary | Peri-procedural morbidity and mortality | Within 30 Days of procedure | Yes | |
Secondary | FilterWire EX and EZ System technical success | Post procedure | Yes | |
Secondary | Carotid Wallstent technical success | Post Procedure | Yes | |
Secondary | system technical success | Post Procedure | Yes | |
Secondary | angiographic success | Post Procedure | Yes | |
Secondary | procedural success | Post Procedure | Yes | |
Secondary | 30-day clinical success | 30 days post procedure | Yes | |
Secondary | peri-procedural overall morbidity | 30 days post procedure | Yes | |
Secondary | one-year clinical success | 1 Year post procedure | Yes | |
Secondary | late stroke, transient ischemic attack (TIA) and death. | 1 year post procedure | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Recruiting |
NCT05993221 -
Deconstructing Post Stroke Hemiparesis
|